Royalty Pharma (RPRX) Expected to Announce Earnings on Thursday

Royalty Pharma (NASDAQ:RPRX) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of $1.02 per share and revenue of $724.69 million for the quarter.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $33.00 on Tuesday. The firm’s fifty day moving average price is $32.45 and its two-hundred day moving average price is $29.65. The stock has a market cap of $19.02 billion, a PE ratio of 22.76, a PEG ratio of 2.31 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. Royalty Pharma has a fifty-two week low of $24.05 and a fifty-two week high of $34.20.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.67%. The ex-dividend date is Friday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Analyst Ratings Changes

Separately, Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.